<DOC>
	<DOCNO>NCT02349503</DOCNO>
	<brief_summary>This Phase 1 , multicenter , open-label , single-dose study evaluate safety tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) NBI-77860 subject congenital adrenal hyperplasia ( CAH ) . The study conduct approximately 15 adolescent female ( 12-18 year age ) document medical diagnosis classic 21-hydroxylase deficiency CAH . The study include three independent dose cohort NBI-77860 ( approximately 5 subject per dose cohort ) . Ascending dos evaluate part sequential-cohort design .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics NBI-77860 Adolescent Females With Congenital Adrenal Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>1 . Have documentation write informed consent , write witnessed assent subject write informed consent subject 's parent legal guardian . 2 . Be good general health . 3 . Have medically confirm diagnosis classic 21hydroxylase deficiency CAH . 4 . Be stable regimen steroidal treatment CAH minimum 30 day baseline ( Night 1 ) expect remain stable throughout study . 5 . Subjects childbearing potential must instruct proper use barrier method contraception agree use hormonal two form nonhormonal contraception ( dual contraception ) consistently screen final study visit 30 day last dose study drug , whichever longer . 6 . Subjects childbearing potential must negative pregnancy test screen negative urine pregnancy test baseline ( Night 1 ) . 7 . Have negative urine drug ( illegal drug ) alcohol breath test screen baseline ( Night 1 ) . 8 . Be willing able adhere study regimen study procedure describe protocol inform consent/assent form , include requirement study center return followup visit . 9 . Be willing provide authorization access personal health information conjunction US Health Insurance Portability Accountability Act ( HIPAA ) . 1 . Have clinically significant unstable medical condition chronic disease , malignancy . 2 . Had medically significant illness within 30 day screen . 3 . Have know suspected differential diagnosis know form classic CAH . 4 . Have history include bilateral adrenalectomy , hypopituitarism , condition require daily therapy orally administer glucocorticoid . 5 . Pregnant lactating female . 6 . Have history epilepsy serious head injury . 7 . Test positive screening hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) , history positive result . 8 . Have recent history ( ≤1 year ) alcohol drug abuse , current evidence substance dependence abuse criterion . 9 . Used investigational drug within 30 day initial screening , plan use investigational drug ( study drug ) study . 10 . Have blood loss ≥250 mL donate blood within 56 day donate plasma within 7 day baseline . 11 . Selfreport consumption 6 caffeinecontaining beverage day within last month baseline .</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Adrenocortical function</keyword>
	<keyword>Adrenal hyperplasia , Congenital</keyword>
	<keyword>21-hydroxylase deficiency</keyword>
	<keyword>Adrenogenital Syndrome</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Female</keyword>
	<keyword>Hyperplasia</keyword>
	<keyword>Adrenal Gland Diseases</keyword>
	<keyword>Congenital Abnormalities</keyword>
	<keyword>Adrenocortical Hyperfunction</keyword>
	<keyword>Disorders Sex Development</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Gonadal Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Metabolism , Inborn Errors</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Steroid Metabolism , Inborn Errors</keyword>
	<keyword>Urogenital Abnormalities</keyword>
	<keyword>Corticotropin Releasing Factor</keyword>
</DOC>